Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
41 hedge funds and large institutions have $6.36M invested in Eiger BioPharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 8 closing their positions.
372% more call options, than puts
Call options by funds: $750K | Put options by funds: $159K
7% less funds holding
Funds holding: 44 → 41 (-3)
16% less capital invested
Capital invested by funds: $7.6M → $6.36M (-$1.24M)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$966K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$89.6K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$78K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.3K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$27.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$223K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$221K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$191K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$140K |
| 5 |
Two Sigma Investments
New York
|
-$129K |
EIGR Hedge Fund Activity: Q3 2015 in Review
41 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2015, worth a combined $6.36M — down 16% from $7.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of EIGR and 5 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $966K. The largest seller was TFS Capital, cutting an estimated $223K.
- 41 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2015, down from 44 in Q2 2015.
- Funds reported $6.36M of Eiger BioPharmaceuticals, Inc. stock for Q3 2015, down 16% quarter-over-quarter.
- 5 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2015 and 8 closed out, a net change of -3 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2015 was Acuta Capital Partners, an estimated $966K added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2015 was TFS Capital, an estimated $223K sold.
Based on aggregated 13F filings for Q3 2015.